This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 955756.

Get closer to animal-free oral drug product development and replace relevant bench works with in silico works as much as possible.

Prof. Christos Reppas

National and Kapodistrian University of Athens

InPharma is an important training as well as scientific network involving several pharmaceutical companies as well as multiple cademical groups from a range of universities. The consortium works with the science of tomorrow and fulfils three major goals, i) to educate our next generation of scientist; ii) to provide new and innovative science, and iii) to bridge across two important parties in the pharmaceutical ecosystem; academia and industry thereby cross seeding perspectives and ideas.

Dr. René Holm

Janssen Pharmaceutica

InPharma offers the opportunity to evaluate and advance different computational applications in oral dosage form development. Unique is an end-to-end modelling approach that embraces aspects of material sciences as well as more biopharmaceutical aspects to design and test oral drug products in a more efficient way compared to traditional approaches in drug product development.

Prof. Martin Kuentz

University of Applied Sciences and Arts Northwestern Switzerland